XPH ETF Analysis: S&P Pharmaceuticals | NYSE
Health | NYSE, USA | Market Cap: 476m USD | 12M Return: 60.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.69M
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The SPDR S&P Pharmaceuticals ETF (XPH) seeks to track the performance of the S&P Pharmaceuticals Select Industry Index by employing a sampling strategy, investing at least 80% of its total assets in securities that comprise the index. The underlying index represents the pharmaceuticals segment of the broader S&P Total Market Index (S&P TMI).
Sampling strategies are commonly used by ETFs to replicate index performance when holding every constituent security is impractical, allowing the fund to mirror the indexs risk and return characteristics through a representative portfolio. The pharmaceuticals segment focuses on companies engaged in the development, manufacturing, and commercialization of drugs and related products.
- IRA Medicare drug price negotiations pressure pharma margins
- FDA approval pipeline drives small-cap pharma revenue growth
- Patent cliff losses weigh on generic competition exposure
As of July 28, 2026, the stock is trading at USD 68.54 with a total of 187,274 shares traded. Over the past week, the price has changed by +2.21%, over one month by +3.21%, over three months by +18.49% and over the past year by +60.93%.
Current recommended Stop Loss: 66.60 (which is 2.8% or 1.3 ATR below the current price).
S&P Pharmaceuticals has no consensus analysts rating.